Shu et al. have published data in murine models showing that draining 
lymph node lymphocytes (DLNL) from sites of tumor immunization can be 
sensitized in vitro (by mixed tumor-lymphocyte culture) and expanded in IL-2 
(32-34). These cells can then be adoptively transferred to tumor-bearing mice 
and show antitumor activity (Table 7). Many of the features of these cells 
are similar to TIL (such as phenotype and tumor specificity patterns) although 
they have a lesser capability to expand in vitro and may be somewhat less 
effective on a cell-f or-cell basis (25,35). These cultured draining lymph 
node cells are currently undergoing Phase I testing by Dr. Alfred Chang at the 
University of Michigan. In order to provide patients undergoing tumor 
immunization with a treatment alternative in the event of failure of the 
primary TIL culture, at the time of resection of inoculation sites (or at 
three weeks after inoculation if no tumor growth is apparent), draining lymph 
nodes will be excisionally biopsied to prepare an alternative T-cell culture 
for adoptive transfer. This will be performed with sensitization using 
autologous cryopreserved tumor (from the original source used for inoculation) 
and IL-2 . These lymph node lymphocytes will be given with systemic IL-2 
exactly as intended for TIL. 
III. PATIENT ELIGIBILITY 
The eligibility of patients for whom cell lines will be established and 
who wi ll be offered the treatment portions of this protocol are the same and 
are listed below: 
1. Patients, age 18 or older, must have histologically confirmed 
metastatic cancer for which standard curative or palliative measures do not 
exist or are no longer effective. These patients have expected survivals of 
six months or less. 
2. The estimated tumor burden of the patient must be at least 10 
grams which is 50 times the weight of tumor cells used for the immunization. 
3. Women of child bearing potential must have a negative pregnancy 
test. 
4. Patients must have a negative HIV test. 
[ 112 ] 
Recombinant DNA Research, Volume 15 
